[Treatment with fluconazole of severe fungal infections in immunocompromised patients].
Fluconazole therapy was evaluated prospectively in 108 patients with immunosupression and serious fungal infections. Patients were enrolled if they had a life-threatening fungal infection and conventional therapy had failed to eradicate infection, had caused serious toxic reactions, or was contraindicated. Patients were treated with 50 to over 400 mg/day initially. AIDS was underlying risk factor in 66.6% of the patients evaluated in the study and in 92.9% of 57 patients with cryptococcal infection. Satisfactory clinical response was observed in 43 patients with active cryptococcal infection and in 39 patients with active candidiasis, 90.7% and 92.3% respectively. Concerning mycologic response, 63.3% and 80.7% of 30 patients with cryptococcal infection and 26 patients with candidiasis respectively had final negative cultures. Eleven patients (10.2%) had adverse effects possibly due to fluconazole therapy. Fluconazole may be effective in the treatment of cryptococcal infection and candidiasis and can be an alternative to conventional antifungal therapy.
Boulos
M
M
Departamento de Doenças Infecciosas e Parasitárias da Faculdade de Medicina da USP, Brasil.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000328:Adult; D002177:Candidiasis / Q000150:complications / Q000188:drug therapy*; D002493:Central Nervous System Diseases / Q000188:drug therapy; D003453:Cryptococcosis / Q000150:complications / Q000188:drug therapy*; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
D015725:Fluconazole
Tratamento pelo fluconazol de pacientes imuno-comprometidos com graves infecçöes fúngicas.